Bodisen Biotech Announces Record First Quarter Earnings of $0.08 Per Share, an Increase of 166%
Friday May 20, 9:30 am ET

Before a Non-recurring Financing Related Charge of $0.03/share

NEW YORK--(BUSINESS WIRE)--May 20, 2005--Bodisen Biotech, Inc., (OTCBB: BBOI, website: (/) announced today that it recorded substantial growth in sales for the first quarter of 2005. The following are some of the key financial highlights for the period ended Mar. 31, 2005 from the company's quarterly report filed with the SEC:

• Revenues of $4,701,675, an increase of 115% compared to the three month period ended Mar. 31, 2004
• Net income of $1,213,436, an increase of 166% compared to the same period in 2004, before a one time financing related charge
• Gross Profit $1,654,178, an increase of 90% compared to the three month period ended Mar. 31, 2004

Revenue.

For the three month period ended March 31, 2005 as compared to the three month period ended March 31, 2004, the Company generated net revenues of $4,701,675 and $2,186,089, respectively, reflecting an increase of $2,515,586 or 115%. The increase in revenues was primarily attributable to increased marketing efforts, which resulted in an increase in our customer base and related volume of recurring and new customer sales.

Net Income.

The Company's net income was $796,733 after charge for the three months ended March 31, 2005, an increase of $375,759 or 89% compared to $420,974 for the three months ended March 31, 2004. The increase is attributed to the substantial growth in the demand for the Company's products throughout China. The net income reflects a one-time charge of $416,703 associated with the aggregate fair value of the warrants which were issued in connection with the $3 million convertible financing which we completed on March 16, 2005.

Ms. Qiong Wang, CEO of Bodisen, commented "2005 will prove to be a significant year of record growth for Bodisen. Our recently completed state of the art manufacturing facility has allowed us to more than double our production capacity to meet increasing customer demand. We look forward to another year of record earnings."

Utilizing proprietary technologies, Bodisen sells over 60 packaged products in 3 product categories: Organic Compound Fertilizer; Organic Liquid Fertilizer; and Pesticides & Insecticides. Bodisen's organic fertilizers can be absorbed by plants within 48 hours while enriching soil conditions without the damaging effects associated with chemical fertilizers.

About Bodisen Biotech, Inc.

Bodisen is headquartered in Shaanxi, China, an agricultural hub of China and the economic gateway to the western regions of China. The Bodisen brand is a highly respected organic brand in China. Its "green" products support the mandate of the Chinese national government to increase crop yields for the purpose of decreasing China's dependency on food imports.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Bodisen Biotech, Inc.
Investor Relations, 212-566-3503
info@bodisen.com

Source: Bodisen Biotech, Inc.